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Resumo
A pré-eclâmpsia (PE) é uma doença espe-
cífica da gestação que, somada às demais 
desordens hipertensivas, constitui impor-
tante causa de morbimortalidade materna 
e perinatal. Tem incidência estimada de 3 
a 14% entre todas as gestações e pode ma-
nifestar-se de diferentes formas clínicas. 
A PE e a doença cardiovascular (DCV) 
possuem mecanismos fisiopatológicos 
semelhantes, como disfunção endotelial, 
alteração metabólica e estresse oxidativo, 
assim como também compartilham alguns 
fatores de risco como obesidade, doença 
renal e diabetes. A exata relação entre PE 
e risco cardiovascular ainda não está to-
talmente elucidada, talvez o estresse me-
tabólico desencadeado na PE provoque a 
lesão vascular que contribui para o desen-
volvimento da DCV e/ou da doença renal 
crônica (DRC) futuramente. Esse risco 
parece ser ainda maior em mulheres com 
história de PE recorrente, severa e eclâmp-
sia. A investigação do antecedente de PE 
pode auxiliar na avaliação do risco futuro 
de DCV e DRC, na prevenção e no diag-
nóstico precoce.
Palavras-chave: Pré-eclâmpsia. Doenças 
Cardiovasculares. Insuficiência Renal 
Crônica. Hipertensão. Proteinúria.
AbstRAct
Preeclampsia (PE) is a pregnancy-specific 
disease which, in addition to other hyper-
tensive disorders, is an important cause 
of maternal and perinatal morbidity and 
mortality.  With an incidence ranging 
from 3 to 14% of all pregnancies worl-
dwide, the disease can present in different 
clinical forms.  PE and cardiovascular 
diseases (CVD) have similar pathophy-
siological mechanisms, such as endothe-
lial dysfunction, metabolic changes and 
oxidative stress, and they also share so-
me risk factors such as obesity, kidney 
disease and diabetes. Although the exact 
relationship between PE and cardiovas-
cular risk has not been fully elucidated, 
PE-triggered metabolic stress may cau-
se vascular injury, thus contributing to 
the development of CVD and/or chronic 
kidney disease (CKD) in the future.  This 
risk appears to be increased especially in 
women with a history of recurrent, severe 
PE and eclampsia. The investigation of a 
history of PE may assist in assessing the 
future risk of CVD and CKD, their pre-
vention and early diagnosis. 
Keywords: Preeclampsia. Cardiovascular 
Diseases. Renal Insufficiency, Chronic. 
Hypertension. Proteinuria.
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IntRoductIon
Preeclampsia (PE) is estimated to occur in 
3-14% of all gestations.1 It is a multisys-
tem disease of unknown cause,2 unique 
to pregnancy, which represents one of 
the main complications of the pregnancy/
puerperal period, either in its pure form 
or superimposed on pre-existing systemic 
arterial hypertension (hereafter referred 
to as arterial hypertension, AH), being an 
important cause of maternal and perinatal 
morbidity and mortality worldwide.3,4 
AH during pregnancy may have dif-
ferent clinical manifestations: PE, defined 
as AH (≥ 140/90mmHg) associated with 
proteinuria (≥ 300 mg/24h or ≥ 1+/ ran-
dom sample dipstick test), with onset af-
ter 20 weeks of gestation, persisting up to 
12 weeks after delivery; chronic arterial 
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hypertension (CAH), defined as increased pressure 
levels before 20 weeks of gestation; PE superimposed 
on HAC, when a patient with CAH develops pro-
teinuria; eclampsia, when PE is complicated by not 
otherwise-explained seizures and; transient gestation-
al hypertension, defined as AH without proteinuria, 
with normalization of the blood pressure up to 12 
weeks after delivery (persistence after this period is 
diagnostic of CAH).5  Recent studies have shown that 
PE may be associated not only with a future risk of 
CAH, but also with the development of cardiovascu-
lar disease (CVD).6,7
Sibai et al. reported a higher rate of CAH, ten 
years after delivery in women with a history of ec-
lampsia and PE, than in those with uneventful preg-
nancies.8 Already in 1961, some authors had reported 
AH persistence in PE-affected women.9
It is noteworthy that PE and CVD share similar 
pathophysiological mechanisms, namely: endothelial 
dysfunction, metabolic alteration and oxidative stress, 
also having common risk factors, such as obesity, 
smoking, advanced age, renal disease and diabetes, 
among others.7,10 Although the precise relationship 
between PE and CVD has not been fully elucidated, 
PE-induced metabolic stress might produce vascular 
injury, the latter contributing to the development of 
CVD11 and chronic kidney disease (CKD).
systemic endotheliAl dysfunction
Although the complex pathophysiology of PE has not 
been fully elucidated, available studies suggest that 
maternal immunologically mediated endothelial da-
mage might lead to generalized vasospasm and coa-
gulation activation.  The “maternal tolerance” which 
normally exists during gestation seems to be lost in 
PE.  Imbalance between trophoblast HLA and natural 
killer cells then triggers a sequence of pathophysiolo-
gical alterations that clinically manifest as PE.12,13 
PE apparently develops in two phases: first there 
are inadequate implantation and placentation, which 
induce poor uterine and placental perfusion, with 
consequent tissue hypoxia and oxidative stress and 
release of some antiangiogenic factors in the maternal 
circulation which, in turn, lead to systemic inflamma-
tion. In the second phase, these factors lead to gen-
eralized endothelial dysfunction, which is responsible 
for the hypertensive syndrome.14
The placenta produces antiangiogenic proteins, 
such as soluble endoglin (sEng) and the soluble vas-
cular endothelial growth factor receptor-1 (sFlt-1), 
which induce endothelial dysfunction, by inhibiting 
pro-angiogenic factors, such as placenta growth fac-
tor (PIGF) and vascular endothelial growth factor 
(VEGF).15-18 There is evidence of elevated sFlt-1 in PE 
and eclampsia, but not in gestational hypertensive 
disease not complicated by proteinuria.19 Some au-
thors have demonstrated that administration of exog-
enous VEGF to humans may lead to regression of the 
AH and proteinuria,20 and that the administration of 
sFlt-1 and anti-VEGF antibodies to rats can produce 
PE-like alterations.21,22 
RepeRcussion of the pRoteinuRiA
The kidneys are among the main organs affected 
by PE, as can be inferred from the importance of 
proteinuria in the definition of the disease.23 The le-
vel of proteinuria is directly related to poorer ma-
ternal and perinatal prognosis, and higher risk of 
complications, such as eclampsia and the HELLP 
syndrome.24,25 Proteinuria can be usually detected, 
on average, three to four weeks before aggravation 
of the clinical picture, allowing early treatment to be 
instituted.26 
Microalbuminuria, a marker of renal endothelial 
injury resulting from local or systemic vascular dam-
age, is associated with higher cardiovascular risk, 
chiefly in hypertensives and diabetics.  The detection 
of microalbuminuria after a PE-complicated gestation 
is attributed to previously undiagnosed renal disease 
which did not fully resolve, or to the presence of risk 
factors which are common to PE and nephropathies.27 
There is increased risk of persistent microalbuminu-
ria or proteinuria after PE, and this may be the main 
cause of kidney disease progression in PE, similarly 
to what happens with type 1 diabetes mellitus pa-
tients.  Laboratory monitoring of women who had 
PE-complicated gestations is thus an important way 
to prevent CVD and CKD.28
Kidney impairment in PE is closely associated with 
podocytopathy.29 As happens with vascular endotheli-
um, VEGF is important for the maintenance of global 
podocyte and glomerular function.30,31 The injured 
podocyte loses its interdigitations, which triggers a 
process of dedifferentiation, with inadequate adher-
ence to the glomerular basement membrane (GBM) 
and consequent elimination of this cell in the urine. 
The denuded GBM favors the development of syne-
chiae and glomerulosclerosis, clinically manifested as 
proteinuria,32 with functional and morphological kid-
ney impairment.33,34 Focal segmental sclerosis, some-
times progressive, may also be found in PE, leading to 
chronic renal failure.35,36 
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Podocyturia may be detected in healthy persons as 
well as in those with CKD, although at significantly 
lower amounts than in those with acute glomerulopa-
thies.37 Assessment of podocyturia and its correlation 
with other renal parameters could help with the diag-
nosis and definition of prognosis of the glomerulopa-
thies, thus contributing to risk reduction.
Because during gestation there is a physiologi-
cal increase in the glomerular filtration rate (GFR) 
and reduction of serum creatinine, even mild eleva-
tions of the latter can indicate renal function deficit. 
Severe PE can lead to deterioration of kidney func-
tion, chiefly in women with previous CKD and GFR 
below 40 mL/min/1.73m2 (< 0.67 mL/s/m2).38 
A retrospective study of 29 pregnant women with 
CKD showed that 65.5% of the kidney injuries were 
only diagnosed during pregnancy, with 75% of the 
patients undergoing their first dialysis during preg-
nancy.  At the end of the follow-up period, over 68% 
of the patients who needed dialysis remained on this 
therapeutic modality, and two received kidney trans-
plants.39 Another study of 52 patients who got preg-
nant after renal transplantation, detected CAH in 
63.5%, and renal dysfunction in 44.2%, PE being 
the main cause.40 These results point to the impact of 
pregnancy on women with CKD, and to the impor-
tance of early diagnosis.
The discussion above underlines the importance of 
a combined nephrologic/obstetric follow-up of CKD 
patients who want to get pregnant, even before con-
ception occurs, in an attempt to prevent complica-
tions.  CKD, which is common and under-reported, 
has high mortality, chiefly due to CVD, the latter be-
ing preventable and treatable if diagnosed early.41
cARdiovAsculAR Risk
PE can lead to permanent metabolic and vascular da-
mage.42 The importance of endothelial dysfunction 
lies not only in its contribution to the PE pathogene-
sis, but also in its relationship with the increased risk 
of subsequent CVD.43
A systematic review and metanalysis,44 shown in 
Table 1, revealed an increased relative risk (RR) of 
CVD after PE, but no increased risk of cancer.  CVD 
is now among the main causes of death worldwide, 
and screening women with a history of PE may be a 
preventive measure to reduce morbidity and mortality 
in the long run.  A study45 of rats with sFlt-1-induced 
PE did not show persistent hypertension after deliv-
ery; although other variables were not analyzed in the 
study, PE may also be an exacerbation of a condition 
antedating the pregnancy.  Nevertheless, more inves-
tigation is necessary before it can be decided whether 
PE is an isolated risk factor for CVD or it is associ-
ated with other pre-existing genetic, environmental 
and socieconomic factors.42
PE is associated with the metabolic syndrome, ac-
cording to a study46 investigating insulin resistance 
and angionegenesis dysfunction, which showed that 
one year after delivery there was a persistent increase 
in serum glucose and sFlt-1, a finding that may indi-
cate that, even without any clinical manifestation, the 
systemic vascular disease was already installed.
It is noteworthy that increased rates of CVD and 
type 2 DM are found after gestational hypertension, 
chiefly with severe PE with pregnancy termination 
before 37 weeks of gestation.47,48 Furthermore, CVD 
and PE share some confounding risk factors, such as 
obesity, the metabolic syndrome and AH.49 Therefore, 
whereas CVD may be a risk factor for PE,50 the latter 
may be a risk factor for CVD.51 
Gestational diabetes is known to be a risk factors 
for type 2 DM and, apparently, PE is a risk factor 
for CFAH, metabolic impairment, endothelial altera-
tions, stroke, acute myocardial infarction, diabetes 
and CKD, including situations in which a renal bi-
opsy is necessary.52 
Persons born to pregnancies complicated by PE 
or gestational hypertension may also have some fu-
ture cardiovascular impairment.53 An increased risk 
of hemorrhagic and ischemic stroke after the ages of 
60-70 years was reported,54 chiefly among those with 
a history of severe PE, probably due to cerebral vascu-
lar dysfunction brought about by development failure 
during intrauterine life.55 It must be highlighted that 
PE and intrauterine growth impairment seem to share 
the same pathogenesis, both being associated with a 
higher prevalence of CVD.42
Table 1 systemAtic Review And metA-
AnAlysis of Risk of cARdiovAsculAR 
diseAse AfteR pReeclAmpsiA
RR (95% CI)
Time 
(years)
Chronic arterial hypertension 3.70 (2.70 – 5.05) 14.10
Stroke 1.81 (1.45 – 2.27) 10.40
Acute coronary disease 2.16 (1.86 – 2.52) 11.70
Venous thromboembolism 1.79 (1.37 – 2.33) 4.70
Mortality 1.49 (1.05 – 2.14) 14.50
Cancer 0.96 (0.73 – 1.27) 17.00
RR: relative risk; CI: confidence interval.
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pReventive meAsuRes
Although primary preventive measures for PE are still 
unavailable, low-dose aspirin (60-100 mg/day) leads 
to a 10% reduction of the risk of PE, and calcium 
intake (1-2 g/day) may optimize vascular reactivi-
ty, despite the fact that the latter approach seems to 
be more consistent in populations on calcium-poor 
diets.56 Routine use of these measures is warran-
ted in CAH patients, as there is a higher risk of PE 
superimposition.57
L-arginine supplementation for pre-existing en-
dothelial dysfunction or at the start of pregnancy 
seems to optimize the obstetric outcome and reduce 
the risk of CVD, although more studies are necessary 
to better understand this possible relationship.58
In spite of the possible usefulness of antioxidants, 
such as vitamins C and E for primary prevention 
of CVD, controlled studies have failed to identify 
a reduction of PE risk in treated patients.  Indeed, 
adverse outcomes, such as membrane rupture, have 
been identified with this approach.  Therefore, 
there is no medical justification at present for the 
use of such medications for the reduction of PE-
associated risks.59,60 As for vitamin D deficiency, be-
cause there is evidence pointing to its possible role 
as an independent risk factor for PE, it could be pre-
ventively used during pregnancy and also in CVD. 
Nevertheless, further research in this group of pa-
tients is warranted.61
Sleep disorders, frequent during pregnancy, may 
also interfere with gestation outcomes through a 
worsening of the systemic inflammatory response, 
increasing the risk of PE, intrauterine growth retar-
dation and future CVD.62 The practice of physical 
exercises before and during pregnancy may reduce 
the incidence of PE, through optimization of vascu-
lar reactivity.63 On the other hand, smoking has been 
long known as an important cardiovascular risk fac-
tor, increasing the incidence of PE and CVD during 
gestation.64
Control of obesity and of the blood lipid and glu-
cose profiles, before, during and after gestation, may 
also prevent CVD65 and obstetric events. 
It is worth emphasizing that persons born to 
PE-complicated gestations are at higher risk of 
metabolic dysfunction and CVD, which leads to a 
vicious cycle through the transmission of genetic 
factors, besides having a higher risk of developing 
PE themselves.66
The acknowledgement of PE as indicative of CVD 
may help with the counseling of these patients on 
the use of oral contraceptives after pregnancy and 
of perimenopausal and postmenopausal hormone 
replacement therapy, with a reduction of the risk of 
thromboembolism.50
Although PE is more frequently found in primi-
gravidas, the precise mechanism of this association 
remains elusive.  Mean blood pressure is lower in the 
second gestation than in the first one, but this dif-
ference disappears after a 2-year interval between the 
deliveries, indicating that other adaptive conditions, 
which have no repercussion on the blood pressure, 
might be involved.67
It is noteworthy that increased levels of C-reactive 
protein (CRP), an indicator of inflammation and 
cardiovascular risk, were detected in women with 
a history of eclampsia, 30 years after the delivery. 
Vascular inflammation, insulin resistance and low 
levels of high-density lipoprotein (HDL) cholesterol 
may increase the risk of PE and subsequent CVD68 
and of prematurity.69 Therefore, women with these 
laboratory alterations should be duly advised and 
treated at any moment in their lives.
Obesity, chiefly of the central type, is related to 
lipotoxicity, which may lead to endothelial dysfunc-
tion, hampering trophoblast invasion, placental 
function and fetal growth.  It is thus important to 
monitor the abdominal circumference before con-
ception and during gestation, and advise on weight 
control after delivery, in order to reduce the risk of 
CVD.70 A cross-sectional study of women who had 
developed PE found, after 10 years, higher diastolic 
blood pressure and body mass index, and greater 
abdominal circumference in comparison with those 
with normal gestations.71
conclusIon
Although delivery is the only cure for PE at present, 
its complications may be prevented if diagnosed 
early.  Better maternal and perinatal prognoses cle-
arly depend on adequate screening, monitoring and 
multidisciplinary follow-up during and even before 
pregnancy. 
Several studies have shown increased risk of CVD 
and CKD in patients with a history of PE.  The cause-
effect relationship of this association has not been 
fully elucidated, but these diseases are known to share 
the same risk factors, probably related to endothelial 
dysfunction. 
In clinical practice, investigation of a previ-
ous history of PE may help with the assessment 
of the risk of CVD and CKD in the future, their 
J Bras Nefrol 2012;34(1):87-93 J Bras Nefrol 2012;34(1):87-93  91
Preeclampsia as indicator of chronic kidney disease
prevention and early diagnosis.  More studies are 
necessary to better understand this disorder and its 
repercussions.
Finally, from an eminently nephrologic point of 
view, the authors of this review consider that physi-
cians (general practitioners, surgeons and specialists 
in any field) must pay attention to a past history of 
PE of any patient they care for, managing these per-
sons as any other member of those at risk of CVD: 
screening for present kidney disease (urinalysis and 
serum creatinine) and following up, or recommend-
ing such approach to their attending physician (ob-
stetrician or gynecologist, for example). 
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